ArBlast Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 26

ArBlast General Information

Description

Developer of regenerative medicines intended to cure degenerative diseases caused by aging. The company offers ocular surface reconstruction using corneal epithelial stem cells that can be transplanted into the patient's eyes, allowing doctors to help restore patients' vision.

Contact Information

Website
www.arblast-usa.com
Formerly Known As
Amniotec, Osteogenesis
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Kobe International Business Center
  • 5-5-2 Minatojima-minamimachi, Chuo-ku
  • Kobe, Hyogo 650-0047
  • Japan
+81
Primary Industry
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • Kobe International Business Center
  • 5-5-2 Minatojima-minamimachi, Chuo-ku
  • Kobe, Hyogo 650-0047
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ArBlast Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 01-Jan-2022 Completed Clinical Trials - General
5. Early Stage VC 01-Nov-2009 Completed Clinical Trials - General
4. Early Stage VC 01-May-2008 Completed Stealth
3. Early Stage VC 01-Oct-2007 Completed Stealth
2. Seed Round 01-Jun-2006 $2.26M $2.26M Completed Stealth
1. Merger of Equals 01-Dec-2005 Completed Stealth
To view ArBlast’s complete valuation and funding history, request access »

ArBlast Patents

  • 62

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

ArBlast Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2008053865-A1 Dispersing agent for ceramic particles and method of preparing monomer suspension Inactive 30-Oct-2006
WO-2008053866-A1 Method of resin molding and resin molding apparatus Inactive 30-Oct-2006
WO-2008018438-A1 Three-dimensional weaving device and three-dimensional weaving method Inactive 07-Aug-2006
WO-2007074896-A1 Composite scaffold for tissue regeneration Inactive 28-Dec-2005
WO-2007032224-A1 Cultured cell sheet and method for preparation thereof Inactive 13-Sep-2005 A61L27/3839
To view ArBlast’s complete patent history, request access »

ArBlast Investors (26)

Investor Name Investor Type Holding Investor Since Participating Rounds
AG Capital (Tokyo) Corporate Venture Capital Minority
Ant Capital Partners PE/Buyout Minority
Aozora Investment Management Asset Manager Minority
Bio Sight Capital Venture Capital Minority
Dai Nippon Printing Corporation Minority
You’re viewing 5 of 26 investors. Get the full list »

Ready to get started?

Request a free trial

ArBlast FAQs

  • When was ArBlast founded?

    ArBlast was founded in 2005.

  • Where is ArBlast headquartered?

    ArBlast is headquartered in Kobe, Japan.

  • What industry is ArBlast in?

    ArBlast’s primary industry is Drug Discovery.

  • Is ArBlast a private or public company?

    ArBlast is a Private company.

  • What is ArBlast’s current revenue?

    The current revenue for ArBlast is .

  • How much funding has ArBlast raised over time?

    ArBlast has raised $10.3M.

  • Who are ArBlast’s investors?

    AG Capital (Tokyo), Ant Capital Partners, Aozora Investment Management, Bio Sight Capital, and Dai Nippon Printing are 5 of 26 investors who have invested in ArBlast.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process